Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

Epigenic Therapeutics Raises $20 Million in Series Angel and Pre-A Funding to Advance Next Generation Gene Editing Therapy

SHANGHAI, Aug. 6, 2022 /PRNewswire/ -- Epigenic Therapeutics Co., Ltd., a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for wide variety of diseases, today announced it has secured$20 million in Series Angel a...

2022-08-07 07:00 3151

BGI's Global Life Science Research Leadership Recognized in 2022 Nature Index

SHENZHEN, China, Aug. 5, 2022 /PRNewswire/ -- BGI's leading global position in life science research has been recognized in the 2022 Nature Index. BGI rose two places to 8th in the world among corporate institutions for its contribution to life science research and was the only Chinese corporate ...

2022-08-05 22:18 5213

WeTrade Group Announced a Strategic Partnership with Jiqing Bio Company, to Exclusively Sell Monkeypox Test Kits and Antigen Tests

BEIJING, Aug. 5, 2022 /PRNewswire/ -- On 5th August, WeTrade Group Inc. ("Wetrade" or the "Company") (NASDAQ: WETG), an emerging growth company engaged in the business of providing software-as-a-services (SAAS) and cloud intelligent systems for micro-businesses, today announced a strategic partn...

2022-08-05 21:10 4782

United BioPharma's Study Reveals New Class of Monoclonal Antibody for Effective Relief of Urticaria Symptoms

New results demonstrate a newer class of anti-IgE antibody, UB-221, with superior neutralization, synthesis reduction, and durable relief in targeting allergic diseases TAIPEI, Aug. 5, 2022 /PRNewswire/ -- United BioPharma (UBP) today announced their latest results featuring unprecedented and u...

2022-08-05 20:45 4729

Yiling's Lianhua Health Products Well-received: CICPE

SHIJIAZHUANG, China, Aug. 5, 2022 /PRNewswire/ -- As China's first national-level consumer expo and the largest such kind in theAsia-pacific region, the 2nd China International Consumer Products Expo (CICPE) attracted many audiences from different countries. And as the TOP 10 Chinese TCM Enterpr...

2022-08-05 15:54 3814

Yiling's Lianhua Health Products Well-received: CICPE

111 to Announce Second Quarter 2022 Unaudited Financial Results on August 25, 2022 - Conference Call to Follow

SHANGHAI, Aug. 5, 2022 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results...

2022-08-05 14:26 1514

Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China

* Collaboration to accelerate the development and access of oncology medicines for cancer patients inChina * Clinical trial programs combining two of Sanofi's prioritized oncology assets with sintilimab, the leading checkpoint inhibitor inChina, to address some of the most prevalent solid tum...

2022-08-04 23:30 3789

Ascletis Announces IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19 Accepted by China NMPA

HANGZHOU, China and SHAOXING, China, Aug. 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the Investigational New Drug (IND) application of ASC10, an oral inhibitor drug candidate targeting RNA-dependent RNA polymerase (RdRp) for COVID-19, has been accep...

2022-08-04 08:10 2435

ST Pharm Presents Phase 1 Clinical Trial Results of HIV Treatment Candidate at AIDS 2022

- STP0404 is the only clinical safety proven HIV treatment candidate with a novel mechanism that can block HIV re-activation. - STP0404 is expected to enter Phase 2a clinical trial in the US in 4Q 2022. SEOUL, South Korea, Aug. 3, 2022 /PRNewswire/ -- ST Pharm Co., Ltd. (237690:KOSDAQ) annou...

2022-08-03 20:00 1722

ProfoundBio Receives FDA "Study May Proceed" Letter for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Welcomes Naomi Hunder, M.D., as Chief Medical Officer

SUZHOU, China and WOODINVILLE, Wash., Aug. 3, 2022 /PRNewswire/ -- ProfoundBio, an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics, announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its investigational ne...

2022-08-03 20:00 1692

Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

SUZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company completed the enrollment of 121 patients for its pha...

2022-08-03 19:38 1329

Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients

-- ASC10 is an oral double prodrug that is rapidly and completely converted in vivo into the active metabolite ASC10-A, which is the same active metabolite of molnupiravir -- Ascletis has filed multiple patent applications for ASC10 and its use globally. Compared with molnupiravir, ASC10 has a n...

2022-08-03 16:50 2110

Approval Of The Comparative Study Between ReCOV And mRNA Vaccines By FDA In The Philippines

TAIZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group",Stock code:02179.HK) is pleased to announce that, the Company has recently received the clinical trial approval for its recombinant protein COVID-19 vaccine,...

2022-08-03 13:09 2791

Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

* ATG-101 is a novel PD-L1/4-1BB bispecific antibody. It is Antengene's first in-house developed molecule with global rights. * ATG-101 demonstrates potent in vivo efficacy in anti-PD-1/PD-L1 resistant mouse tumor models. SHANGHAI and HONG KONG, Aug. 3, 2022 /PRNewswire/ -- Antengene Corpora...

2022-08-03 08:30 1868

Sciwind Biosciences Announces Positive Topline Results from 20-week Phase 2 Clinical Trial of XW003 (Ecnoglutide), a novel long-lasting GLP-1 analogue, in Adult Patients with Type 2 Diabetes in China

- Robust HbA1c reduction of 2.4% was observed with 1.2 mg XW003 dose - Up to 88% of participants achieved HbA1c ≤ 7% and up to 72% achieved HbA1c ≤6.5% at the end of the 20-week treatment - XW003 was safe and well tolerated with gastrointestinal side effects as the most commonly reported adve...

2022-08-03 08:00 1801

Lynk Pharmaceuticals Announces IND Approval of LNK01004 for Atopic Dermatitis in China

HANGZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that its innovative drug LNK01004, has been approved by National Medical Products Administration (NMPA) for clinical tr...

2022-08-03 08:00 2363

Ablaze Pharma Aligned The Strategic Agreement With Wenjiang District Government of Chengdu to Build-up the Innovative R&D and Manufacturing Center for Targeted Radiopharmaceutical Therapies

SHANGHAI, Aug. 3, 2022 /PRNewswire/ -- In July 2022, Ablaze Pharma and Wenjiang District Government ofChengdu jointly signed the strategic agreement during the Conference of Major Advanced Manufacturing Projects by Foreign Direct Investment. About 26,000㎡ of industrial land is selected in the Che...

2022-08-03 08:00 1850

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2 clinical trial in Q4 2022 PHILADELPHIA and FLORENCE, Italy, Aug. 2, 2022 /PRNewswire/ -- Context Therapeutics Inc. ("Context" or the "Company") (...

2022-08-02 22:49 2567

GenKOre develops hypercompact base editing system

DAEJEON, South Korea , Aug. 2, 2022 /PRNewswire/ -- GenKOre (homepage: www.genkore.com ), a biotech start-up in Korea, had a study on the development of hypercompact adenine base editors (ABEs) published on Nature Chemical Biology onAugust 2, 2022.

2022-08-02 22:44 1927

GenKOre develops hypercompact base editing system

Metabolon Awarded ISO 9001:2015 Recertification

ISO 9001:2015 certificate re-issued to Metabolon following continued demonstrated ability to meet customer, statutory, and regulatory standards MORRISVILLE, N.C., Aug. 2, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance drug development and ...

2022-08-02 20:57 1592

1 ... 119 120 121122123 124 125 ... 294